Interactions between circulating tumour cells (CTCs) and platelets are thought to inhibit natural killer(NK)-cell-induced lysis. We attempted to correlate CTC numbers in men with advanced prostate cancer with platelet counts and circulating lymphocyte numbers.
Prostate cancer (PC) is a polygenic disease with multiple gene interactions. Therefore, a detailed analysis of its epidemiology and evaluation of risk factors can help to identify more accurate predictors of aggressive disease.
Focal therapy has emerged as a promising option to treat well-selected men with localised prostate cancer while preserving healthy prostate tissue and key structures, such as the urethral sphincter and neurovascular bundles.
The Göteborg 2 prostate cancer (PC) screening (G2) trial evaluates screening with prostate-specific antigen (PSA) followed by magnetic resonance imaging (MRI) in case of elevated PSA levels. To assess the safety of using a 2-yr interval in men who were previously screened positive with PSA but had negative MRI or positive MRI with a negative […]
To provide commentary on the disparities in access to clinical trials and precision oncology specific to Black men with Prostate Cancer (PCa) in the United States and lend a general framework to aid in closing these gaps.
Bladder cancer (BC) is the fifth most prevalent cancer in Canada, with 9000 Canadians diagnosed each year.1 While smoking is the most important risk factor, environmental and occupational carcinogens have been found to significantly contribute to BC rates.
We aimed to describe the oncological outcomes after radical cystectomy and chemo-radiation for localized small cell bladder cancer (SCBC). This population-based analysis of localized SCBC from 1985-2018 in British Columbia included an analysis (analysis 1) of cancer-specific survival (CSS) and overall survival (OS) of patients treated with curative-intent radical cystectomy (RC) and radiation (RT), and […]
Ashish Kamat: Hello, and welcome to Uro Today’s Bladder Cancer Center of Excellence. I’m Ashish Kamat, professor of urologic oncology and cancer research at MB Anderson Cancer Center. And it’s a pleasure to welcome today, assistant attending Richard Matulewicz, who is now with Memorial Sloan Kettering, to present to us his data and his presentation […]
(UroToday.com) Since 2015, several phase 3 randomized controlled trials have demonstrated that adding either androgen pathway inhibitors or chemotherapy to testosterone suppression can prolong overall survival for men diagnosed with metastatic hormone-sensitive metastatic prostate cancer (mHSPC). The STAMPEDE study has specifically demonstrated a survival advantage in mHSPC with the addition of the androgen synthesis inhibitor abiraterone […]
(UroToday.com) Poly (ADP-ribose) polymerase inhibitors provide clinical benefit across multiple cancers with germline or somatic alterations in the BRCA1 and BRCA2 genes, as well as other select genes within the homologous recombination DNA repair pathway. The PARP inhibitors olaparib and rucaparib are approved for use in metastatic castration-resistant prostate cancer (mCRPC) in patients harboring certain genomic […]
